Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07815548
PHASE4

Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth

Sponsor: Shandong University

View on ClinicalTrials.gov

Summary

This multicenter randomized controlled study aims to systematically evaluate the efficacy and safety of Saccharomyces boulardii sachets versus rifaximin in the treatment of small intestinal bacterial overgrowth (SIBO), with a focus on symptom relief and the impacts of anxiety-depressive factors on the treatment of abdominal distension and diarrhea in SIBO patients. The findings will offer a new non-antibiotic therapeutic option for SIBO, especially for patients with antibiotic resistance or those requiring long-term management, and lay a theoretical foundation for the clinical application of intestinal microecological regulators.

Official title: Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Abdominal Distension and Diarrhea Related to Small Intestinal Bacterial Overgrowth:a Non-inferiority Randomized Controlled Study

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

222

Start Date

2026-09-10

Completion Date

2027-12-31

Last Updated

2026-09-15

Healthy Volunteers

No

Interventions

DRUG

Saccharomyces boulardii sachets

0.5 g, orally, twice daily for 2 weeks

DRUG

Rifaximin (Xifaxan)

0.4 g, orally, twice daily for 2 weeks

Locations (1)

Qilu Hospital of Shandong University

Jinan, Shandong, China